At a Glance
- Companies: Eli Lilly and Company (NYSE: LLY); Ventyx Biosciences, Inc. (Nasdaq: VTYX)
- Location: Indianapolis (Lilly); San Diego (Ventyx)
- Deal value: $1.2bn equity value ($14/share, 62% premium to 30‑day VWAP); closes H1 2026
- Focus area: NLRP3 inhibitors (VTX2735 pericarditis, VTX3232 Parkinson’s/CV risk); IBD assets
- Next steps: Integrate Ventyx pipeline into Lilly’s inflammation R&D
What happened?
Eli Lilly has agreed to acquire Ventyx Biosciences for $1.2 billion in an all‑cash deal, purchasing all outstanding shares at $14 each—a 62% premium to the 30‑day VWAP ending 5 January 2026. The transaction, Lilly’s first M&A of 2026, closes H1 2026 subject to shareholder approval and regulatory clearance (no financing condition).
Why does it matter?
Ventyx’s NLRP3 inhibitors target chronic inflammation in cardiometabolic, neurodegenerative and autoimmune diseases, complementing Lilly’s GLP‑1 dominance (Mounjaro/Zepbound). VTX2735 (peripheral NLRP3i) is phase 2 for recurrent pericarditis; VTX3232 (CNS‑penetrant) showed CV risk factor reductions in phase 2 and completed Parkinson’s biomarker study. IBD assets VTX002 (S1P1R) and VTX958 (TYK2) are also phase 2.
Who’s behind it?
Ventyx develops oral small molecules for inflammation, with NLRP3 as a key sensor pathway linked to multiple diseases. Lilly, with $1tn+ market cap from GLP‑1s, diversifies into inflammation amid Keytruda‑like cliffs elsewhere.
How was it achieved?
Lilly buys the full company, integrating Ventyx’s pipeline; boards approved, with 10% shareholder support agreements. Premium reflects Ventyx’s $10bn+ peak sales potential.
What’s next?
Close H1 2026; advance NLRP3 inhibitors to phase 3, leveraging Lilly’s scale for cardiometabolic/neuro applications.
What are people saying?
Lilly CSPO Daniel Skovronsky: Ventyx “strengthens our ability to deliver advances” in inflammation. Ventyx CEO Raju Mohan: Lilly’s “resources and passion for innovative oral drugs” ideal partner. Analysts see NLRP3 read‑through to peers.